摘要
纤溶酶原激活物抑制剂-1是纤溶系统的主要调节因子,通过抑制组织型纤溶酶原活化剂影响血浆纤溶和凝血系统的平衡,引起或者加速心血管疾病的发生发展。纤溶酶原激活物抑制剂-1对心血管疾病的诊断、预后,尤其对冠心病的诊断、分型、危险分层、预后及经皮冠状动脉介入治疗后的再狭窄的判断有重要指导意义。心血管疾病相关的的辅助检查中,纤溶酶原激活物抑制剂-1将提供一种新的选择。
Plasminogen Activator Inhibitor-1 ( PAI-1 ) is a primary regulator of the fibrinolytic system. It is becoming a recognized risk factor in the development of cardiovascular diseases through its inhibition of the effects of t-PA. PAI-1 is also very important in the diagnosis and the risk stratification of coronary heart disease. PAI-1 may provide a new option in the auxiliary examination of cardiovascular diseases.
出处
《心血管病学进展》
CAS
2009年第4期696-699,共4页
Advances in Cardiovascular Diseases
关键词
纤溶酶原激活物抑制剂-1
冠心病
原发性高血压
深静脉血栓形成
肺血栓栓塞
脑血栓形成
plasminogen activator inhibitor-1
coronary heart disease
primary hypertension
deep vein thrombosis
pulmonary thromboembolism
cerebral thrombosis